HRP20200009T1 - Angiotenzin ii u kombinaciji za liječenje hipotenzije - Google Patents
Angiotenzin ii u kombinaciji za liječenje hipotenzije Download PDFInfo
- Publication number
- HRP20200009T1 HRP20200009T1 HRP20200009TT HRP20200009T HRP20200009T1 HR P20200009 T1 HRP20200009 T1 HR P20200009T1 HR P20200009T T HRP20200009T T HR P20200009TT HR P20200009 T HRP20200009 T HR P20200009T HR P20200009 T1 HRP20200009 T1 HR P20200009T1
- Authority
- HR
- Croatia
- Prior art keywords
- preparation
- angiotensin
- treatment
- subject
- catecholamine
- Prior art date
Links
- 102000005862 Angiotensin II Human genes 0.000 title claims 6
- 101800000733 Angiotensin-2 Proteins 0.000 title claims 6
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 title claims 6
- 229950006323 angiotensin ii Drugs 0.000 title claims 6
- 208000001953 Hypotension Diseases 0.000 title 1
- 230000036543 hypotension Effects 0.000 title 1
- 150000003943 catecholamines Chemical class 0.000 claims 5
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 claims 4
- 102000002852 Vasopressins Human genes 0.000 claims 4
- 108010004977 Vasopressins Proteins 0.000 claims 4
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 claims 4
- 229960003726 vasopressin Drugs 0.000 claims 4
- 230000004872 arterial blood pressure Effects 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/085—Angiotensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Claims (8)
1. Pripravak koji sadrži angiotenzin II za uporabu u liječenju subjekta koji ima visoki izlazni šok i koji je podvrgnut liječenju kateholaminom ili vazopresinom, naznačen time što:
tretman uključuje primjenu pripravka koji sadrži angiotenzin II brzinom od 2- 10 ng/kg/min ili 20 ng/kg/min i smanjuje brzinu kojom se daje kateholamin ili vazopresin; i
tretman je učinkovit za podizanje i održavanje srednjeg arterijskog tlaka (MAP) subjekta iznad 65 mm Hg.
2. Pripravak za uporabu prema zahtjevu 1, naznačen time što je subjekt otporan na kateholamin.
3. Pripravak za uporabu prema zahtjevu 1, naznačen time što se angiotenzin II i kateholamin ili vazopresin daju intravenozno.
4. Pripravak za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time što je subjekt čovjek.
5. Pripravak prema bilo kojem od prethodnih zahtjeva, naznačen time što je subjekt podvrgnut liječenju kateholaminom.
6. Pripravak prema bilo kojem od prethodnih zahtjeva, naznačen time što je subjekt podvrgnut liječenju vazopresinom.
7. Pripravak prema bilo kojem od prethodnih zahtjeva, naznačen time što sadrži primjenu pripravka koji sadrži angiotenzin II brzinom od 2-10 ng/kg/min.
8. Pripravak prema bilo kojem od zahtjeva 1 do 6, naznačen time što obuhvaća primjenu pripravka koji sadrži angiotenzin II brzinom od 20 ng/kg/min.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361917576P | 2013-12-18 | 2013-12-18 | |
US201461955706P | 2014-03-19 | 2014-03-19 | |
PCT/US2014/071186 WO2015095535A1 (en) | 2013-12-18 | 2014-12-18 | Angiotensin ii alone or in combination for the treatment of hypotension |
EP14872684.7A EP2986308B1 (en) | 2013-12-18 | 2014-12-18 | Angiotensin ii in combination for the treatment of hypotension |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20200009T1 true HRP20200009T1 (hr) | 2020-03-20 |
Family
ID=53367119
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20200009TT HRP20200009T1 (hr) | 2013-12-18 | 2020-01-03 | Angiotenzin ii u kombinaciji za liječenje hipotenzije |
Country Status (23)
Country | Link |
---|---|
US (7) | US9220745B2 (hr) |
EP (2) | EP2986308B1 (hr) |
JP (3) | JP6824739B2 (hr) |
KR (3) | KR20220028125A (hr) |
CN (3) | CN112546197A (hr) |
AU (2) | AU2014364528C1 (hr) |
BR (1) | BR112016013961A2 (hr) |
CA (1) | CA2933601A1 (hr) |
CY (1) | CY1122604T1 (hr) |
DK (1) | DK2986308T3 (hr) |
EA (1) | EA037823B1 (hr) |
ES (1) | ES2771749T3 (hr) |
HR (1) | HRP20200009T1 (hr) |
HU (1) | HUE047062T2 (hr) |
IL (1) | IL246162B (hr) |
LT (1) | LT2986308T (hr) |
MX (2) | MX2016008108A (hr) |
NZ (1) | NZ721089A (hr) |
PL (1) | PL2986308T3 (hr) |
PT (1) | PT2986308T (hr) |
RS (1) | RS59804B1 (hr) |
SI (1) | SI2986308T1 (hr) |
WO (1) | WO2015095535A1 (hr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9572856B2 (en) | 2009-12-16 | 2017-02-21 | The George Washington University a Congressionally Chartered Not-for-Profit Corporation | Method of treating low blood pressure |
KR20220028125A (ko) | 2013-12-18 | 2022-03-08 | 더 조지 워싱턴 유니버시티 | 저혈압의 치료를 위한 안지오텐신 ii 단독 또는 조합 |
BR112017000303A2 (pt) * | 2014-07-08 | 2017-11-07 | La Jolla Pharma Co | métodos para o tratamento de hipotensão |
US9919022B2 (en) | 2015-03-20 | 2018-03-20 | Arthur J. ATKINSON, JR. | Use of angiotensin II (AII) receptor agonists to prevent or reduce hemodialysis-associated skeletal muscle cramps |
EP3400000B1 (en) | 2016-01-07 | 2023-12-06 | La Jolla Pharma, LLC | Methods for administering angiotensin ii |
AU2017205479A1 (en) * | 2016-01-07 | 2018-08-16 | La Jolla Pharmaceutical Company | Methods of administering vasopressors |
WO2018191678A1 (en) * | 2017-04-14 | 2018-10-18 | La Jolla Pharmaceutical Company | Methods for administering angiotensin ii |
TW201927331A (zh) * | 2017-12-15 | 2019-07-16 | 美商拉荷亞製藥公司 | 血管收縮素組合物及與其相關之方法 |
WO2023244552A1 (en) * | 2022-06-15 | 2023-12-21 | Virginia Commonwealth University | Methods for fluid resuscitation of an organ donor |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU181008B (en) | 1980-01-18 | 1983-05-30 | Richter Gedeon Vegyeszet | Process for producing angiotenzin-ii analogues of antagonistic activity containing sarcosyl-group at the 1-positon,and an alpha-hydroxy-carboxylic acid at the 8-position |
US5216025A (en) * | 1989-09-13 | 1993-06-01 | Board Of Regents, The University Of Texas System | Nitric oxide synthesis inhibitors for potentiating the action of pressor agents in certain hypotensive patients |
US5444067A (en) | 1993-08-30 | 1995-08-22 | Merck & Co., Inc. | Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety |
WO2002098906A1 (en) | 2001-06-04 | 2002-12-12 | Human Genome Sciences, Inc. | Methods and compositions for modulating ace-2 activity |
US7115266B2 (en) | 2001-10-05 | 2006-10-03 | Cytos Biotechnology Ag | Angiotensin peptide-carrier conjugates and uses thereof |
EP1699495A2 (en) | 2003-11-06 | 2006-09-13 | Amersham Health AS | Conjugates of angiotensin ii and an imaging moiety |
NO20034952D0 (no) | 2003-11-06 | 2003-11-06 | Amersham Health As | Farmasöytiske forbindelser |
FR2880807B1 (fr) * | 2005-01-19 | 2007-04-13 | Aguettant Sa Lab | Composition pharmaceutique injectable |
ATE507243T1 (de) | 2005-09-29 | 2011-05-15 | Fibrogen Inc | Verfahren zur senkung des blutdrucks |
CA2633013A1 (en) | 2005-12-30 | 2007-07-12 | Howard Florey Institute Of Experimental Physiology And Medicine | A method of treatment |
US20070293552A1 (en) | 2006-06-15 | 2007-12-20 | Gorczynski Richard J | Antihypertensive therapy method |
WO2008130217A1 (en) * | 2006-08-08 | 2008-10-30 | Applied Nanosystems B.V. | Cyclic angiotensin analogs |
JP2010510196A (ja) | 2006-11-17 | 2010-04-02 | ダ・ボルテラ | オイドラギット被覆を施した亜鉛/ペクチンビーズを使用する結腸送達 |
WO2009009907A1 (en) | 2007-07-18 | 2009-01-22 | The University Of British Columbia | Use of vasopressin-receptor agonists for the treatment of septic shock |
EP2161030A1 (en) * | 2008-09-09 | 2010-03-10 | Rijksuniversiteit te Groningen | Oxytocin formulations and uses thereof |
JP2012510468A (ja) | 2008-11-28 | 2012-05-10 | アボット・ラボラトリーズ | 安定な抗体組成物およびこれを安定させるための方法 |
US9572856B2 (en) | 2009-12-16 | 2017-02-21 | The George Washington University a Congressionally Chartered Not-for-Profit Corporation | Method of treating low blood pressure |
FR2959414B1 (fr) * | 2010-04-30 | 2016-01-08 | Luc Quintin | Combinaison de molecules aux fins de traitement d'hypotension survenant au cours du choc septique, cardiogenique, ou anaphylactique refractaire, ou hemorragique terminal, apres correction de la volemie et de l'etat de mal asthmatique refractaire |
JP2013532635A (ja) | 2010-07-14 | 2013-08-19 | カンバーランド エマージング テクノロジーズ,インコーポレーテッド | トロンボキサン−a2受容体アンタゴニストでの肝腎症候群および肝性脳症の治療方法 |
CN105592855A (zh) | 2013-04-26 | 2016-05-18 | 拉卓拉药物公司 | 用于治疗肾衰竭的组合物和方法 |
KR20220028125A (ko) | 2013-12-18 | 2022-03-08 | 더 조지 워싱턴 유니버시티 | 저혈압의 치료를 위한 안지오텐신 ii 단독 또는 조합 |
US20150286797A1 (en) | 2014-04-02 | 2015-10-08 | David R. Ratto | System and method for administering medication |
BR112017000303A2 (pt) * | 2014-07-08 | 2017-11-07 | La Jolla Pharma Co | métodos para o tratamento de hipotensão |
EP3400000B1 (en) | 2016-01-07 | 2023-12-06 | La Jolla Pharma, LLC | Methods for administering angiotensin ii |
AU2017205479A1 (en) | 2016-01-07 | 2018-08-16 | La Jolla Pharmaceutical Company | Methods of administering vasopressors |
WO2018191678A1 (en) | 2017-04-14 | 2018-10-18 | La Jolla Pharmaceutical Company | Methods for administering angiotensin ii |
TW201927331A (zh) | 2017-12-15 | 2019-07-16 | 美商拉荷亞製藥公司 | 血管收縮素組合物及與其相關之方法 |
-
2014
- 2014-12-18 KR KR1020227004084A patent/KR20220028125A/ko active Application Filing
- 2014-12-18 PL PL14872684T patent/PL2986308T3/pl unknown
- 2014-12-18 LT LTEP14872684.7T patent/LT2986308T/lt unknown
- 2014-12-18 CN CN202011494632.XA patent/CN112546197A/zh active Pending
- 2014-12-18 KR KR1020167019427A patent/KR102399383B1/ko active IP Right Grant
- 2014-12-18 EP EP14872684.7A patent/EP2986308B1/en active Active
- 2014-12-18 CN CN201480075899.1A patent/CN106061493A/zh active Pending
- 2014-12-18 AU AU2014364528A patent/AU2014364528C1/en active Active
- 2014-12-18 BR BR112016013961A patent/BR112016013961A2/pt not_active Application Discontinuation
- 2014-12-18 NZ NZ721089A patent/NZ721089A/en unknown
- 2014-12-18 RS RS20200021A patent/RS59804B1/sr unknown
- 2014-12-18 DK DK14872684.7T patent/DK2986308T3/da active
- 2014-12-18 JP JP2016539318A patent/JP6824739B2/ja active Active
- 2014-12-18 CA CA2933601A patent/CA2933601A1/en active Pending
- 2014-12-18 US US14/575,127 patent/US9220745B2/en active Active
- 2014-12-18 KR KR1020237012136A patent/KR20230051721A/ko not_active Application Discontinuation
- 2014-12-18 MX MX2016008108A patent/MX2016008108A/es unknown
- 2014-12-18 EA EA201691258A patent/EA037823B1/ru unknown
- 2014-12-18 HU HUE14872684A patent/HUE047062T2/hu unknown
- 2014-12-18 WO PCT/US2014/071186 patent/WO2015095535A1/en active Application Filing
- 2014-12-18 CN CN202010824424.5A patent/CN111920939A/zh active Pending
- 2014-12-18 ES ES14872684T patent/ES2771749T3/es active Active
- 2014-12-18 EP EP19197866.7A patent/EP3607962A1/en active Pending
- 2014-12-18 PT PT148726847T patent/PT2986308T/pt unknown
- 2014-12-18 SI SI201431450T patent/SI2986308T1/sl unknown
-
2015
- 2015-11-13 US US14/941,301 patent/US10028995B2/en active Active
-
2016
- 2016-06-09 IL IL246162A patent/IL246162B/en active IP Right Grant
- 2016-06-17 MX MX2020011190A patent/MX2020011190A/es unknown
-
2018
- 2018-03-01 US US15/909,617 patent/US10493124B2/en active Active
- 2018-09-19 US US16/135,608 patent/US10765722B2/en active Active
-
2019
- 2019-04-12 US US16/382,850 patent/US11096983B2/en active Active
- 2019-08-23 JP JP2019153144A patent/JP7175506B2/ja active Active
-
2020
- 2020-01-03 HR HRP20200009TT patent/HRP20200009T1/hr unknown
- 2020-01-13 CY CY20201100026T patent/CY1122604T1/el unknown
- 2020-11-26 AU AU2020277230A patent/AU2020277230A1/en active Pending
-
2021
- 2021-07-20 US US17/380,311 patent/US11559559B2/en active Active
-
2022
- 2022-07-14 JP JP2022113327A patent/JP2022137224A/ja active Pending
-
2023
- 2023-01-23 US US18/157,933 patent/US20230226141A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20200009T1 (hr) | Angiotenzin ii u kombinaciji za liječenje hipotenzije | |
PH12017502092A1 (en) | Topical pharmaceutical compositions | |
MX2020001513A (es) | Agentes de union a clec9a y su uso. | |
EA201490254A1 (ru) | Комбинированное лечение гепатита с | |
MX2020005054A (es) | Combinacion de dos agentes antivirales para el tratamiento de hepatitis c. | |
WO2015095811A3 (en) | Combination therapy with neoantigen vaccine | |
WO2015085143A3 (en) | Therapeutic agents for skin diseases and conditions | |
BR112015027282A8 (pt) | formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet | |
WO2017194782A3 (en) | Therapeutic targeting of non-cellular structures | |
UA109991C2 (xx) | Карбаматні сполуки, їх отримання і застосування | |
EA201650134A1 (ru) | Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором | |
MX2023000796A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
MX2015012536A (es) | Combinacion de agentes antivirales de accion directa y ribavirina para el tratamiento de pacientes con vhc. | |
MX2016012799A (es) | Metodos para tratar el virus de la hepatitis c. | |
BR112015025955A2 (pt) | tratamentos anticancerosos com anticorpos anti-egfr apresentando uma baixa fucosilação | |
MX2017005134A (es) | Tratamiento del cáncer con inmunoestimuladores. | |
MX2020011107A (es) | Regimen de glicosidasa para el tratamiento de enfermedades infecciosas. | |
MX2018000240A (es) | Metodos para tratar el vhc. | |
MX363507B (es) | Metodos para administrar óxido nítrico a la sangre arterial o arterializada. | |
WO2014071168A3 (en) | Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients | |
MX2016012722A (es) | Metodos para tratar el virus de la hepatitis c. | |
CL2015002627A1 (es) | Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol | |
WO2015063613A3 (en) | Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents | |
EA201690686A1 (ru) | Способ профилактики или лечения системной красной волчанки и/или волчаночного нефрита | |
WO2014140680A8 (en) | Dosing regimen for use of celgosivir as an antiviral therapeutic for dengue virus infection |